GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » QSAM Biosciences Inc (OTCPK:QSAM) » Definitions » Cash Ratio

QSAM Biosciences (QSAM Biosciences) Cash Ratio : 1.34 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is QSAM Biosciences Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. QSAM Biosciences's Cash Ratio for the quarter that ended in Dec. 2023 was 1.34.

QSAM Biosciences has a Cash Ratio of 1.34. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for QSAM Biosciences's Cash Ratio or its related term are showing as below:

QSAM' s Cash Ratio Range Over the Past 10 Years
Min: 0.14   Med: 1.05   Max: 1.74
Current: 1.34

During the past 13 years, QSAM Biosciences's highest Cash Ratio was 1.74. The lowest was 0.14. And the median was 1.05.

QSAM's Cash Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.94 vs QSAM: 1.34

QSAM Biosciences Cash Ratio Historical Data

The historical data trend for QSAM Biosciences's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

QSAM Biosciences Cash Ratio Chart

QSAM Biosciences Annual Data
Trend Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.74 0.14 1.34

QSAM Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.66 0.28 0.26 1.34

Competitive Comparison of QSAM Biosciences's Cash Ratio

For the Biotechnology subindustry, QSAM Biosciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


QSAM Biosciences's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, QSAM Biosciences's Cash Ratio distribution charts can be found below:

* The bar in red indicates where QSAM Biosciences's Cash Ratio falls into.



QSAM Biosciences Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

QSAM Biosciences's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=1.386/1.033
=1.34

QSAM Biosciences's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=1.386/1.033
=1.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


QSAM Biosciences  (OTCPK:QSAM) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


QSAM Biosciences Cash Ratio Related Terms

Thank you for viewing the detailed overview of QSAM Biosciences's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


QSAM Biosciences (QSAM Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
9442 Capital of Texas Highway North, Plaza 1, Suite 500, Austin, TX, USA, 78759
QSAM Biosciences Inc is a clinical-stage novel radiopharmaceutical company. The company is developing treatments for bone cancer and related diseases.
Executives
Adam King officer: Chief Financial Officer 9442 CAPITAL OF TEXAS HWY N, PLAZA 1, SUITE 500, AUSTIN TX 78759
Link Jr. Charles J director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010
Adriann Sax director 7 DORSET COURT,, EAST BRUNSWICK, NJ 08816
David Charles Link director 2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Douglas R Baum director, officer: CEO & Director 5000 RAFFEE COVE, AUSTIN TX 78731-1132
C Richard Piazza director, officer: Executive Chairman 2236 EAST MALL, SUITE 208, UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER A1 V6T 1Z3
Checkmate Strategic Capital Holdings, Llc other: Member of 13(d) 10% owner grp 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Checkmate Strategic Capital 2, Llc 10 percent owner, other: See Explanation of Responses 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Checkmate Capital Group, Llc 10 percent owner, other: Member of 13(d) 10% owner grp 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Charles Thomas Paschall other: Member of 13(d) 10% owner grp 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Christopher M. Nelson director, officer: General Counsel 420 ROYAL PALM WAY, SUITE #100, PALM BEACH FL 33480
Scott W. Whitney director, other: Former Director 96 WINDSOR DRIVE, PINE BROOK NJ 07058
Kevin Bolin director, officer: Former Chairman & CEO 1081 ROSEDALE DRIVE, ATLANTA GA 30306
Tristan Peitz director, other: Former Director C/O Q2POWER TECHNOLOGIES, INC., 420 ROYAL PALM WAY, #100, PALM BEACH FL 33480
Joel David Mayersohn director 350 EAST LAS OLAS BLVD. #1150, FORT LAUDERDALE FL 33301

QSAM Biosciences (QSAM Biosciences) Headlines

From GuruFocus

QSAM Biosciences Announces Reverse Stock Split Effective March 10, 2022

By GuruFocusNews GuruFocusNews 03-09-2022

QSAM Biosciences Provides 2022 Update and 2023 Milestones to Shareholders

By Stock market mentor Stock market mentor 01-10-2023

QSAM Biosciences Appoints Adriann Sax to Board of Directors

By GuruFocusNews GuruFocusNews 01-25-2022